Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Century Therapeutics' Other Non-Current Assets rose 1127.16% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 1127.16%. This contributed to the annual value of $2.8 million for FY2024, which is 4007.07% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Other Non-Current Assets is $3.2 million, which was up 1127.16% from $2.7 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Other Non-Current Assets high stood at $3.2 million for Q3 2025, and its period low was $1.7 million during Q1 2022.
  • Moreover, its 4-year median value for Other Non-Current Assets was $2.0 million (2022), whereas its average is $2.3 million.
  • In the last 5 years, Century Therapeutics' Other Non-Current Assets skyrocketed by 4345.63% in 2024 and then crashed by 444.44% in 2025.
  • Over the past 4 years, Century Therapeutics' Other Non-Current Assets (Quarter) stood at $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then surged by 40.07% to $2.8 million in 2024, then grew by 13.96% to $3.2 million in 2025.
  • Its Other Non-Current Assets stands at $3.2 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.